Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-06-09 Notice of Dividend Amou…
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2024年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Implementation Announcement" for the year 2024 by Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the equity distribution plan approved at the 2024 Annual General Meeting held on May 21, 2025. The content includes specifics on stock dividends, cash dividends, tax implications, record dates, ex-dividend dates, and shareholding changes. The document is relatively short (2150 characters) and focuses on the announcement of the dividend distribution plan and its implementation rather than providing a full annual report or financial statements. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders. Therefore, the document should be classified as DIV with high confidence.
2025-06-09 Chinese
2025年股票期权激励计划股票期权首次授予结果公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial grant results of a stock option incentive plan by Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the number of options granted, recipients, exercise conditions, performance targets, and the impact on financials. It is a formal disclosure of the stock option grant event, including specific data on allocation and terms. This type of document is a capital/financing update related to equity incentives and stock option grants, not a full financial report or audit. It is not a report publication announcement since it contains substantive details rather than just a notice of report availability. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters but contains detailed substantive information about the stock option grant, so it is not just an announcement of a report publication or a regulatory filing.
2025-06-08 Chinese
关于与专业投资机构合作参与投资设立产业基金的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding its cooperation with professional investment institutions to participate in the establishment of an industrial fund. It details the partnership agreement, fund structure, investment objectives, and potential risks. The document is a formal disclosure about a capital investment activity and fund formation, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but rather informs shareholders and the public about a financing and investment update. The document length is 3195 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-06-08 Chinese
关于山西锦波生物医药股份有限公司2024年年度股东会的法律意见书
Regulatory Filings
2025-05-22 Chinese
山西锦波生物医药股份有限公司章程
Governance Information Classification · 100% confidence The document is the Articles of Association (章程) of Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. It details the company's organizational structure, shareholder rights, board responsibilities, share issuance and transfer rules, and other governance matters. It is a legal and governance document that sets out the internal rules and regulations of the company. There is no indication that this is an announcement, a financial report, or a meeting transcript. The content aligns with the definition of Governance Information (CGR), which covers the company's internal rules, board structure, and governance practices.
2025-05-22 Chinese
2024年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2024 Annual General Meeting (AGM) resolution announcement for Shanxi Jinbo Biopharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results on various proposals including the 2024 annual report, financial statements, remuneration, and other corporate matters. The document is a formal announcement of the resolutions passed at the AGM, not the full annual report or financial statements themselves. The length is 3824 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-05-22 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.